Antibody-drug conjugates--an emerging class of cancer treatment.
View/ Open
Date
2016-02-16ICR Author
Author
Diamantis, N
Banerji, U
Type
Journal Article
Metadata
Show full item recordAbstract
Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.
Collections
Subject
Humans
Neoplasms
Antibodies, Monoclonal
Immunoconjugates
Research team
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Language
eng
Date accepted
2015-10-26
License start date
2016-02
Citation
British journal of cancer, 2016, 114 (4), pp. 362 - 367
Publisher
NATURE PUBLISHING GROUP